Di-Methyl-Histone H3 (Lys79) Antibody

What is Di-Methyl-Histone H3 (Lys79) and what is its biological function?

Di-Methyl-Histone H3 (Lys79) (H3K79me2) is a specific post-translational modification where lysine 79 of histone H3 is dimethylated by the Dot1 methyltransferase enzyme. Histone H3 is one of the four core histone proteins (H2A, H2B, H3, and H4) that make up the nucleosome core particle, which consists of 147 base pairs of DNA wrapped around an octamer of these core histones. H3K79 methylation primarily functions as a marker of inactive chromatin regions and plays a critical role in transcriptional silencing. This modification is particularly important because it affects chromatin structure and accessibility, thereby regulating gene expression. Current research indicates that silencing proteins such as Sir3 may function by blocking Dot1 methylation activity, establishing an important regulatory mechanism in chromatin dynamics .

How does Di-Methyl-Histone H3 (Lys79) differ from mono- and tri-methylated forms?

Di-Methyl-Histone H3 (Lys79) represents one of three possible methylation states at this residue, with distinct functional implications:

Each methylation state creates different binding surfaces for effector proteins, leading to distinct downstream effects. High-quality antibodies demonstrate no cross-reactivity between these states, allowing researchers to study each specifically. H3K79me2 is particularly important as it represents the predominant form involved in transcriptional silencing and chromatin compaction mechanisms .

What are the validated applications for Di-Methyl-Histone H3 (Lys79) antibodies?

Di-Methyl-Histone H3 (Lys79) antibodies have been validated for multiple experimental applications focusing on epigenetic research:

These applications have been validated by major epigenetics consortia including modENCODE and NIH Roadmap Epigenomics Mapping Consortium, establishing standardized protocols for reliability and reproducibility. The antibodies consistently detect a protein band at approximately 17 kDa, corresponding to histone H3 .

How should researchers optimize ChIP protocols when using Di-Methyl-Histone H3 (Lys79) antibodies?

For optimal chromatin immunoprecipitation (ChIP) results with Di-Methyl-Histone H3 (Lys79) antibodies, researchers should follow these methodological considerations:

• Starting material: Use 10 μg of chromatin (approximately 4 × 10^6 cells) per immunoprecipitation.

• Antibody amount: Use 10 μl of antibody per ChIP reaction for optimal enrichment.

• Crosslinking: Standard 1% formaldehyde for 10 minutes at room temperature works well for H3K79me2.

• Sonication: Adjust sonication conditions to generate chromatin fragments between 200-500 bp.

• Controls: Include:

  • Input sample (non-immunoprecipitated chromatin)

  • Negative control (IgG or non-specific antibody)

  • Positive control (antibody against abundant mark like H3K4me3)

When transitioning to ChIP-Seq, reduce the antibody amount to 5 μl to minimize background. For challenging samples or low-abundance targets, consider using enzymatic ChIP kits which have been validated with these antibodies. Researchers should verify antibody specificity using peptide competition assays before proceeding with full experiments to ensure specificity for H3K79me2 over mono- and tri-methylated forms .

How specific are commercial Di-Methyl-Histone H3 (Lys79) antibodies and what cross-reactivity issues should researchers be aware of?

Commercial Di-Methyl-Histone H3 (Lys79) antibodies demonstrate high specificity for their target modification. Rigorous validation testing has shown:

What species cross-reactivity exists for Di-Methyl-Histone H3 (Lys79) antibodies?

Di-Methyl-Histone H3 (Lys79) antibodies exhibit broad species cross-reactivity due to the high conservation of histone H3 sequences across species:

How can researchers use Di-Methyl-Histone H3 (Lys79) antibodies in multi-omics approaches?

Integrating Di-Methyl-Histone H3 (Lys79) antibody-based techniques with other -omics approaches provides comprehensive insights into epigenetic regulation:

• ChIP-Seq + RNA-Seq: Correlate H3K79me2 distribution with transcriptome data to identify genes regulated by this modification.

  • Analysis approach: Calculate enrichment scores at promoters/gene bodies and correlate with expression levels.

  • Expected pattern: H3K79me2 enrichment often inversely correlates with gene expression.

• CUT&Tag-Seq + ATAC-Seq: Combine H3K79me2 mapping with chromatin accessibility data.

  • Integration method: Overlay H3K79me2 peaks with accessible chromatin regions.

  • Typical finding: H3K79me2-enriched regions often show reduced chromatin accessibility.

• ChIP-Seq + Hi-C: Analyze the relationship between H3K79me2 and three-dimensional genome organization.

  • Analysis framework: Examine H3K79me2 distribution at topologically associating domain (TAD) boundaries.

  • Emerging pattern: H3K79me2 often marks boundary regions between active and inactive chromatin domains.

• Multi-mark ChIP-Seq: Perform sequential ChIP or parallel ChIP experiments with H3K79me2 and other histone marks.

  • Implementation: Use compatible antibodies and optimized protocols for multiple immunoprecipitations.

  • Biological insight: Identifies genomic regions with specific combinatorial histone modification patterns.

These integrated approaches require careful experimental design and computational analysis pipelines that account for the specific characteristics of each data type. For optimal results, researchers should use matched cell populations and process samples in parallel to minimize technical variation .

How does Di-Methyl-Histone H3 (Lys79) distribution change during cellular differentiation and development?

H3K79me2 undergoes dynamic changes during cellular differentiation and development, making it a valuable marker for studying epigenetic reprogramming:

During early embryonic development, global H3K79me2 levels are dynamically regulated. The mark is initially depleted during zygotic genome activation, then gradually reestablished in a lineage-specific manner. In studies of cellular reprogramming (e.g., iPSC generation), H3K79me2 patterns must be reset to achieve complete epigenetic reprogramming.

To study these dynamics, researchers should employ time-course experiments with ChIP-Seq or CUT&Tag assays at defined developmental timepoints. Single-cell techniques now allow analysis of H3K79me2 distribution in heterogeneous populations during differentiation, revealing epigenetic trajectories that would be masked in bulk analysis .

What are common pitfalls when using Di-Methyl-Histone H3 (Lys79) antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with Di-Methyl-Histone H3 (Lys79) antibodies:

When troubleshooting ChIP experiments specifically, researchers should verify sufficient chromatin fragmentation (200-500 bp) and include spike-in controls to normalize for technical variation. The addition of 10-30% glycerol to antibody storage buffer can improve stability and consistent performance over time. For definitive validation of antibody specificity, researchers can use samples from DOT1L inhibitor-treated cells or DOT1L knockout models, which should show significant reduction in H3K79me2 signal .

How can researchers accurately quantify changes in H3K79me2 levels across experimental conditions?

Accurate quantification of H3K79me2 levels requires appropriate normalization strategies and controls:

• Western Blot Quantification:

  • Always normalize H3K79me2 signal to total H3 levels using a modification-independent H3 antibody.

  • Use a standard curve of recombinant histones for absolute quantification.

  • Employ fluorescent secondary antibodies for wider linear detection range compared to chemiluminescence.

• ChIP-qPCR Quantification:

  • Express enrichment as percent of input or fold enrichment over control regions.

  • Include invariant regions (housekeeping genes) as internal references.

  • Consider the % input method: % Input = 2^(Ct[adjusted input] - Ct[IP]) × 100%

• ChIP-Seq/CUT&Tag Quantification:

  • Use spike-in normalization with exogenous chromatin (e.g., Drosophila chromatin).

  • Apply appropriate normalization factors for library depth.

  • Consider differential binding analysis software (e.g., DiffBind, MACS2).

• Statistical Analysis:

  • For small-scale experiments: Perform at least three biological replicates and use appropriate statistical tests (t-test, ANOVA).

  • For genome-wide analyses: Control for multiple testing using FDR correction methods.

  • Report effect sizes and confidence intervals, not just p-values.

For studying dynamic changes, time-course experiments with consistent sampling and processing protocols are essential. When comparing different cell types or tissues, account for differences in chromatin compaction and accessibility that might affect antibody binding efficiency .

How are researchers using Di-Methyl-Histone H3 (Lys79) antibodies in single-cell epigenomic analyses?

Single-cell epigenomic technologies are revolutionizing our understanding of H3K79me2 distribution and heterogeneity:

• Single-Cell CUT&Tag:

  • Implementation: Combines antibody-directed tagmentation with single-cell isolation.

  • Advantage: Provides H3K79me2 profiles in individual cells with minimal input material.

  • Current limitation: Lower sensitivity than bulk methods, detecting primarily high-occupancy sites.

  • Data analysis: Requires specialized computational pipelines to address sparsity and technical noise.

• Single-Cell Multi-Omics:

  • Approach: Simultaneous profiling of H3K79me2 and other molecular features (RNA, DNA methylation).

  • Technologies: CITE-seq adaptations, scM&T-seq modifications.

  • Biological insight: Reveals direct correlation between H3K79me2 patterns and gene expression in the same cell.

• Spatial Epigenomics:

  • Emerging methods: Combining H3K79me2 immunofluorescence with in situ sequencing or imaging mass cytometry.

  • Application: Mapping H3K79me2 distribution within tissue architecture.

  • Development stage: Currently in early implementation by pioneering labs.

• Computational Integration:

  • Challenge: Integrating sparse single-cell H3K79me2 data with other epigenetic marks.

  • Solution: Transfer learning approaches that leverage relationships established in bulk data.

  • Future direction: Machine learning models to predict chromatin states from limited features.

These advanced applications require highly specific antibodies with optimized protocols for low-input samples. Researchers pioneering these methods often need to perform extensive validation using known H3K79me2 targets before applying them to biological questions .

What is the role of H3K79me2 in disease states and how are antibodies being used to study these connections?

H3K79me2 dysregulation has been implicated in multiple disease processes, with antibody-based studies providing critical insights:

DOT1L inhibitors are being developed as therapeutic agents, particularly for MLL-rearranged leukemias. Researchers use H3K79me2 antibodies to:

• Assess inhibitor efficacy through global H3K79me2 reduction.

• Identify "addiction" to H3K79me2 in specific cancer subtypes.

• Monitor treatment response using ChIP-qPCR at sentinel loci.

• Develop companion diagnostics to identify patients likely to respond to DOT1L inhibition.

Patient-derived xenograft models allow in vivo tracking of H3K79me2 changes during disease progression and treatment. ChIP-Seq studies comparing normal and diseased tissues have identified disease-specific H3K79me2 signatures that correlate with transcriptional programs driving pathogenesis. These findings highlight the potential of H3K79me2 as both a biomarker and therapeutic target in multiple disease contexts .

How do researchers choose between polyclonal and monoclonal Di-Methyl-Histone H3 (Lys79) antibodies for specific applications?

Selecting the appropriate antibody format requires weighing several factors:

Decision framework for selecting antibody format:

• For genome-wide studies (ChIP-Seq, CUT&Tag): Prefer monoclonal antibodies like Cell Signaling Technology's D15E8 XP Rabbit mAb (#5427) for consistent specificity and lower background.

• For challenging samples or technique development: Consider polyclonal antibodies like Active Motif's pAb (#39143) that recognize multiple epitopes.

• For quantitative comparative studies: Recombinant monoclonal antibodies provide the highest consistency for detecting subtle changes in H3K79me2 levels.

• For novel applications: Test both formats in pilot experiments to determine which performs better in your specific system.

When long-term reproducibility is critical, recombinant antibodies offer superior lot-to-lot consistency. Regardless of format, researchers should always validate antibody performance in their specific experimental system .

How do CUT&Tag and ChIP-Seq methodologies compare when using Di-Methyl-Histone H3 (Lys79) antibodies?

CUT&Tag and ChIP-Seq represent complementary approaches for genome-wide H3K79me2 profiling, each with distinct advantages:

Key methodological considerations:

• For H3K79me2, CUT&Tag often provides superior signal-to-noise ratios, particularly at regions with moderate enrichment that might be missed by ChIP-Seq.

• Peak calling algorithms may need adjustment between methods:

  • ChIP-Seq: Standard MACS2 parameters work well

  • CUT&Tag: Requires lower stringency settings to account for sharper peaks

• Integration challenges:

  • Direct comparison between ChIP-Seq and CUT&Tag datasets requires careful normalization

  • Differential enrichment analyses should only compare data generated by the same method

• Practical recommendation:

  • For new studies: CUT&Tag offers technical advantages for H3K79me2 profiling

  • For comparison with existing datasets: Match the methodology used in previous work

Recent technological developments combining antibody-directed tagmentation with single-cell isolation have enabled single-cell CUT&Tag analyses of H3K79me2, opening new avenues for studying heterogeneity in epigenetic regulation .

What are the current consensus best practices for Di-Methyl-Histone H3 (Lys79) antibody-based experiments?

Based on consolidated findings from multiple sources, the following best practices are recommended:

• Antibody Selection and Validation:

  • Verify specificity using peptide competition assays

  • Test reactivity in your specific experimental system

  • Consider recombinant monoclonal antibodies for long-term studies

• Experimental Design:

  • Include appropriate controls (input, IgG, positive control regions)

  • Perform biological replicates (minimum of three)

  • Use spike-in controls for quantitative comparisons

• Application-Specific Recommendations:

  • ChIP/ChIP-Seq: 10 μg chromatin with 5-10 μl antibody

  • Western Blot: 1:1000 dilution with total H3 loading control

  • CUT&Tag: 0.5-1 μl antibody with optimized buffer conditions

  • Immunofluorescence: 1:200 dilution with antigen retrieval

• Data Analysis and Interpretation:

  • Apply appropriate normalization strategies

  • Consider genomic context when interpreting H3K79me2 distribution

  • Integrate with other epigenetic and transcriptomic data

These recommendations have emerged from extensive method development and validation efforts by academic laboratories and consortia. They represent the current consensus in the field, though researchers should remain aware that methodologies continue to evolve .

What emerging research directions are likely to employ Di-Methyl-Histone H3 (Lys79) antibodies in novel ways?

Several cutting-edge research areas are poised to leverage H3K79me2 antibodies in innovative applications:

• Dynamic Live-Cell Tracking:

  • Development of H3K79me2-specific intracellular antibodies (mintbodies)

  • Real-time visualization of epigenetic changes during cellular processes

  • Challenge: Creating antibody derivatives that maintain specificity while functioning in living cells

• Therapeutic Biomarker Development:

  • H3K79me2 profiles as predictive markers for DOT1L inhibitor response

  • Companion diagnostic development for precision medicine applications

  • Opportunity: Standardizing H3K79me2 ChIP protocols for clinical samples

• Synthetic Biology Applications:

  • Engineered reader domains for H3K79me2-dependent gene regulation

  • CRISPR-based targeted manipulation of H3K79me2 patterns

  • Frontier: Creating synthetic circuits responsive to H3K79me2 status

• Multi-Modal Single-Cell Analysis:

  • Combined profiling of H3K79me2, chromatin accessibility, and transcription

  • Spatial mapping of H3K79me2 distribution in tissue contexts

  • Innovation: Development of multiplexed single-cell methods to capture epigenetic heterogeneity

• Evolutionary Epigenomics:

  • Comparative analysis of H3K79me2 function across diverse species

  • Understanding conservation and divergence of this epigenetic mechanism

  • Challenge: Adapting protocols for non-model organisms

These emerging directions will require continued refinement of antibody technology, particularly development of recombinant antibodies with enhanced specificity and novel functional properties. Researchers pioneering these approaches will need to integrate antibody-based methods with complementary technologies to address complex biological questions about H3K79me2 function .